Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Intermittent Explosive Disorder (IED)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 May 2022
Price :
$35
*
At a glance
- Drugs Deudextromethorphan (Primary)
- Indications Impulse control disorders
- Focus Therapeutic Use
- Sponsors Avanir Pharmaceuticals
- 29 Jan 2019 Status changed from active, no longer recruiting to discontinued.
- 29 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Feb 2018 New trial record